癌性恶液质临床建议路径  

Recommendation on Clinical Pathway of Cancer Cachexia

作　　者：马怀幸 李苏宜 MA Huai-xing;LI Su-yi(Anhui Provincial Cancer Hospital,The First Affiliated Hospital of University of Science and Technology of China(West Campus),Hefei 230031,China)

机构地区：[1]中国科学技术大学附属第一医院西区(安徽省肿瘤医院),安徽合肥230031

出　　处：《肿瘤学杂志》2022年第12期1007-1013,共7页Journal of Chinese Oncology

基　　金：安徽省肿瘤医院青年基金(2020YJQN019)

摘　　要：癌性恶液质临床发生率高,作为一种特殊营养不良状态,有其自身的特点及病理生理机制,单纯的营养支持难以逆转。目前为止,抗恶液质药物治疗进展缓慢,癌性恶液质缺乏公认的标准治疗模式。但癌性恶液质并非指疾病的终末期,及时有效地干预,可改善该类患者的临床结局。全文就癌性恶液质的发生机制、分期与标准、“综合治疗”策略等方面进行论述。Cancer cachexia has a high clinical incidence.As a special malnutrition,it has its own characteristics and pathophysiological mechanism.It can not be fully reversed by conventional nutritional support.At present,the development of anti-cachexia drug treatment is slow and there are currently few approved standard treatments for cancer cachexia.However,cancer cachexia does not refer to the final stage of cancer.Timely and effective intervention can improve the clinical outcome of these patients.The mechanism,staging and criteria,and“comprehensive treatment”strategy of cancer cachexia were analyzed in this paper.

关 键 词：癌性恶液质 临床路径 综合治疗 

分 类 号：R730.5[医药卫生—肿瘤]